Zheng, Shengxing, Wang, Qian, He, Qian, Song, Xiaorong, Ye, Duyun, Smith, F. Gao (Fang Gao), Jin, Shengwei and Lian, QingQuan. (2011) Novel biphasic role of lipoxinA4 on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts. Mediators of Inflammation, Vol.2011 (No.745340). ISSN 1466-1861

Preview

PDF WRAP_Gao_745340.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (1450Kb)

Abstract

Fibroblasts are important to host defence and immunity, can also as initiators of inflammation as well. As the endogenous "braking signal", Lipoxins can regulate anti-inflammation and the resolution of inflammation. We investigated the effect of lipoxinA4 on the expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts. We demonstrated that the expression of cyclooxygenase-2 protein was significantly increased and peaked initially at 6 hours, with a second increase, with maximal levels occurring 24 hours after lipopolysaccharide challenge. ProstaglandinE2 levels also peaked at 6 hours, and prostaglandinD2 levels were increased at both 6 and 24 hours. Exogenous lipoxinA4 inhibited the first peak of cyclooxygenase-2 expression as well as the production of prostaglandinE2 induced by lipopolysaccharide in a dose-dependent manner. In contrast, exogenous lipoxinA4 increased the second peak of cyclooxygenase-2 expression as well as the production of prostaglandinD2 induced by lipopolysaccharide in a dose-dependent manner. LipoxinA4 receptor mRNA expression was markedly stimulated by lipopolysaccharide but inhibited by lipoxinA4. We present evidence for a novel biphasic role of lipoxinA4 on the expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts, whereby LXA4 has an anti-inflammatory and proresolving activity in lung fibroblasts following LPS stimulation.

Item Type:	Journal Article
Subjects:	Q Science > QP Physiology
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Lipoxins, Fibroblasts, Cyclooxygenase 2
Journal or Publication Title:	Mediators of Inflammation
Publisher:	Hindawi Publishing Corporation
ISSN:	1466-1861
Date:	2011
Volume:	Vol.2011
Number:	No.745340
Number of Pages:	9
Identification Number:	10.1155/2011/745340
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	Guo jia zi ran ke xue ji jin wei yuan hui (China) [National Natural Science Foundation of China] (NSFC), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents
Grant number:	30772088 (NSFC), 81070061 (NSFC)
References:	[1] H. Kirpalani and J. Gauldie, “Differentiation and effector function of pulmonary fibroblasts,” in Asthma and Rhinitis, W. W. Busse and S. T. Holgate, Eds., pp. 539–553, Blackwell Scientific, Boston, Mass, USA, 1995. [2] C. D. Buckley, D. Pilling, J. M. Lord, A. N. Akbar, D. Scheel- Toellner, and M. Salmon, “Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation,” Trends in Immunology, vol. 22, no. 4, pp. 199–204, 2001. [3] R. S. Smith, T. J. Smith, T. M. Blieden, and R. P. Phipps, “Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation,” The American Journal of Pathology, vol. 151, no. 2, pp. 317–322, 1997. [4] A. Zdaˇrilov´a, A. R. Svobodov´a, K. Chytilov´a, V. ˇSim´anek, and J. Ulrichov´a, “Polyphenolic fraction of Lonicera caerulea L. fruits reduces oxidative stress and inflammatory markers induced by lipopolysaccharide in gingival fibroblasts,” Food and Chemical Toxicology, vol. 48, no. 6, pp. 1555–1561, 2010. [5] B. Ros ´on, J. Carratal`a, N. Fern´andez-Sab´e, F. Tubau, F. Manresa, and F. Gudiol, “Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia,” Archives of Internal Medicine, vol. 164, no. 5, pp. 502–508, 2004. [6] C. W. Chow, M. T. H. Abreu, T. Suzuki, and G. P. Downey, “Oxidative stress and acute lung injury,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 4, pp. 427– 431, 2003. [7] J. Beck, R. Garcia, G. Heiss, P. S. Vokonas, and S. Offenbacher, “Periodontal disease and cardiovascular disease,” Journal of Periodontology, vol. 67, no. 10, pp. 1123–1137, 1996. [8] W. L. Smith, R. Michael Garavito, and D. L. DeWitt, “Prostaglandin endoperoxide H syntheses (cyclooxygenases)- 1 and -2,” The Journal of Biological Chemistry, vol. 271, no. 52, pp. 33157–33160, 1996. [9] C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001. [10] C. Y. Wu, P. L. Chi, H. L. Hsieh, S. F. Luo, and C. M. Yang, “TLR4-dependent induction of vascular adhesion molecule-1 in rheumatoid arthritis synovial fibroblasts: roles of cytosolic phospholipase a 2α/ cyclooxygenase-2,” Journal of Cellular Physiology, vol. 223, no. 2, pp. 480–491, 2010. [11] I. Morita, “Distinct functions of COX-1 and COX-2,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 165– 175, 2002. [12] H. Mizuno, C. Sakamoto, K. Matsuda et al., “Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice,” Gastroenterology, vol. 112, no. 2, pp. 387–397, 1997. [13] D. W. Gilroy, P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby, “Inducible cyclooxygenase may have anti-inflammatory properties,” NatureMedicine, vol. 5, no. 6, pp. 698–701, 1999. [14] L. Vong, J. G. P. Ferraz, R. Panaccione, P. L. Beck, and J. L. Wallace, “A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-termremission from ulcerative colitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 12023–12027, 2010. [15] H. K¨uhn and V. B. O’Donnell, “Inflammation and immune regulation by 12/15-lipoxygenases,” Progress in Lipid Research, vol. 45, no. 4, pp. 334–356, 2006. [16] B. D. Levy, “Lipoxins and lipoxin analogs in asthma,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 3-4, pp. 231–237, 2005. [17] C. N. Serhan, “Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators,” Journal of Periodontology, vol. 79, no. 8, pp. 1520– 1526, 2008. [18] S. J. O’Meara, K. Rodgers, and C. Godson, “Lipoxins: update and impact of endogenous pro-resolution lipid mediators,” Reviews of Physiology, Biochemistry and Pharmacology, vol. 160, pp. 47–70, 2008. [19] C. N. Serhan, “Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways,” Annual Review of Immunology, vol. 25, pp. 101–137, 2007. [20] C. N. Serhan, S. Yacoubian, and R. Yang, “Anti-inflammatory and proresolving lipid mediators,” Annual Review of Pathology, vol. 3, pp. 279–312, 2008. [21] B. D. Levy, “Lipoxins and lipoxin analogs in asthma,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 3-4, pp. 231–237, 2005. [22] C. Bandeira-Melo, M. F. Serra, B. L. Diaz et al., “Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia,” Journal of Immunology, vol. 164, no. 2, pp. 1029–1036, 2000. [23] C. L. Karp, L. M. Flick, K. W. Park et al., “Defective lipoxinmediated anti-inflammatory activity in the cystic fibrosis airway,” Nature Immunology, vol. 5, no. 4, pp. 388–392, 2004. [24] C. L. Karp, L. M. Flick, R. Yang, J. Uddin, and N. A. Petasis, “Cystic fibrosis and lipoxins,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 3-4, pp. 263–270, 2005. [25] S. H. Wu, X. H. Wu, C. Lu, L. Dong, and Z. Q. Chen, “Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 1, pp. 65–72, 2006. [26] C. Bonnans, K. Fukunaga,M. A. Levy, and B. D. Levy, “Lipoxin A4 regulates bronchial epithelial cell responses to acid injury,” American Journal of Pathology, vol. 168, no. 4, pp. 1064–1072, 2006. [27] J. C. Bonner, A. B. Rice, J. L. Ingram et al., “Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis,” American Journal of Pathology, vol. 161, no. 2, pp. 459–470, 2002. [28] R.Medeiros, G. B. Rodrigues, C. P. Figueiredo et al., “Molecular mechanisms of topical anti-inflammatory effects of lipoxin A4 in endotoxin-induced uveitis,” Molecular Pharmacology, vol. 74, no. 1, pp. 154–161, 2008. [29] M. Tamm, M. Roth, M. Malouf et al., “Primary fibroblast cell cultures from transbronchial biopsies of lung transplant recipients,” Transplantation, vol. 71, no. 2, pp. 337–339, 2001. [30] E. Motohashi, H. Kawauchi, H. Endo et al., “Regulatory expression of lipoxin A4 receptor in physiologically estrus cycle and pathologically endometriosis,” Biomedicine and Pharmacotherapy, vol. 59, no. 6, pp. 330–338, 2005. [31] J. P. Louboutin, B. A. S. Reyes, L. Agrawal, C. R. Maxwell, E. J. Van Bockstaele, and D. S. Strayer, “Blood-brain barrier abnormalities caused by exposure toHIV-1 gp120 - Protection by gene delivery of antioxidant enzymes,” Neurobiology of Disease, vol. 38, no. 2, pp. 313–325, 2010. [32] M. Raval, P. G. Frank, L. Laury-Kleintop, G. Yan, and S. Lanza- Jacoby, “Celecoxib combined with atorvastatin prevents progression of atherosclerosis,” Journal of Surgical Research, vol. 163, no. 2, pp. e113–e122, 2010. [33] J. O’Brien, T. Lyons, J. Monks et al., “Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species,” American Journal of Pathology, vol. 176, no. 3, pp. 1241–1255, 2010. [34] A. L¨uhrmann, K. Grote, M. Stephan, T. Tschernig, and R. Pabst, “Local pulmonary immune stimulation by the Toll-like receptor 2 and 6 ligand MALP-2 in rats is age dependent,” Immunology Letters, vol. 108, no. 2, pp. 167–173, 2007. [35] J. U. Scher and M. H. Pillinger, “15d-PGJ2: the antiinflammatory prostaglandin?” Clinical Immunology, vol. 114, no. 2, pp. 100–109, 2005. [36] E. Estenssoro, A. Dubin, E. Laffaire et al., “Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome,” Critical Care Medicine, vol. 30, no. 11, pp. 2450–2456, 2002. [37] F. Frutos-Vivar, N. Nin, and A. Esteban, “Epidemiology of acute lung injury and acute respiratory distress syndrome,” Current Opinion in Critical Care, vol. 10, no. 1, pp. 1–6, 2004. [38] G. D. Rubenfeld, E. Caldwell, E. Peabody et al., “Incidence and outcomes of acute lung injury,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1685–1693, 2005. [39] L. B. Ware and M. A. Matthay, “The acute respiratory distress syndrome,” The New England Journal ofMedicine, vol. 342, no. 18, pp. 1334–1349, 2000. [40] D. W. Gilroy, T. Lawrence, M. Perretti, and A. G. Rossi, “Inflammatory resolution: new opportunities for drug discovery,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 401–416, 2004. [41] C. N. Serhan, “Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways,” Annual Review of Immunology, vol. 25, pp. 101–137, 2007. [42] S. W. Jin, L. Zhang, Q. Q. Lian et al., “Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1,” Anesthesia and Analgesia, vol. 104, no. 2, pp. 369–377, 2007. [43] D. Takai, T. Nagase, and T. Shimizu, “New therapeutic key for cystic fibrosis: a role for lipoxins,” Nature Immunology, vol. 5, no. 4, pp. 357–358, 2004. [44] A. Tomlinson, I. Appleton, A. R. Moore et al., “Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenin- induced pleurisy,” British Journal of Pharmacology, vol. 113, no. 3, pp. 693–698, 1994. [45] K. Fukunaga, P. Kohli, C. Bonnans, L. E. Fredenburgh, and B. D. Levy, “Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury,” Journal of Immunology, vol. 174, no. 8, pp. 5033–5039, 2005. [46] C. Bandeira-Melo, M. F. Serra, B. L. Diaz et al., “Cyclooxygenase- 2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia,” Journal of Immunology, vol. 164, no. 2, pp. 1029–1036, 2000.
URI:	http://wrap.warwick.ac.uk/id/eprint/36802

Request changes to a record

Actions (login required)

View Item